Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

41.74 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 41.74
Today's Range 41.74 - 41.74
52wk Range 29.20 - 42.15
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
The single-dose vials will also increase supply, the drug giant says. 
Via Investor's Business Daily
Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Quest Diagnostics are also monitoring demand and expanding testing... 
Via Benzinga

Performance

YTD
+14.83%
+14.83%
1 Month
+3.32%
+3.32%
3 Month
+33.35%
+33.35%
6 Month
+26.37%
+26.37%
1 Year
+13.76%
+13.76%

More News

Read More
Biotech Bull Market: 3 Ways To Play It
Via Talk Markets
Topics Economy
Exposures Interest Rates
IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter
Via Investor's Business Daily
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
Via The Motley Fool
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
Via Benzinga
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?
Via Benzinga
Exposures Product Safety
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
Via The Motley Fool
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
Via Benzinga
Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects
Via Benzinga
Here's Why Eli Lilly Stock Dropped 12% Last Month
Via The Motley Fool
Roche Considers Selling Cancer Data Specialist Flatiron Health Business, Highlights Challenges With Start-Up Acquisitions
Via Benzinga
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
Via Benzinga
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
Via The Motley Fool
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
Via The Motley Fool
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Via Benzinga
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
Via The Motley Fool
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Via Benzinga
This Big Pharma Could Become a Leading Weight-Loss Stock. Should You Buy It?
Via The Motley Fool
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche
Via The Motley Fool
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
Via Investor's Business Daily
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Via Benzinga
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
Via Benzinga
Topics Stocks
Exposures US Equities
New Data for Genentech’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions
From Genentech
Via Business Wire
Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.